Altunay, Betül
Goedicke, Andreas
Winz, Oliver H.
Hertel, Fabian
von Mallek, Dirk
Meszaros, Levente K.
Chand, Gitasha
Biersack, Hans-Jürgen
Stickeler, Elmar
Krauss, Katja
Mottaghy, Felix M. http://orcid.org/0000-0002-7212-6521
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (project 331065168 - GRK2375, project 445703531 - Clinical Research Unit 5011, project 321137804 - Research Unit 2591)
Nanomab Technology (UK) Ltd.
Avicenna Studienwerk
RWTH Aachen University
Article History
Received: 13 July 2022
Accepted: 28 November 2022
First Online: 9 December 2022
Declarations
:
: All reported investigations were conducted in accordance with § 13 (2b) German Medicinal Products Act (AMG) and § 83 (3) German Radiation Protection Act (StrlSchG), as well as the updated Declaration of Helsinki, § 37 (Unproven Interventions in Clinical Practice), which includes the priority of approved procedures.
: All patients have been referred for additional examination, informed about the individual medical decision of this new diagnostic procedure and about possible risks and side effects, and signed a written informed consent form. The authors affirm that participants also provided informed consent for the publication of the images.
: All patients have been referred for additional examination, informed about the individual medical decision of this new diagnostic procedure and about possible risks and side effects, and signed a written informed consent form. The authors affirm that participants also provided informed consent for the publication of the images.
: LKM and GC are employees of NanoMab Technology Ltd., HJB is on the advisory board of NanoMab Technology Ltd., and FMM is a medical advisor for NanoMab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH and has recently received institutional grants from NanoMab Technology Ltd., Siemens, and GE Precision Healthcare LLC. The other authors declare no conflict of interest.